SUMMARY OF SUBGROUP DECISIONS FOR GMMMG APPROVAL – 11th November 2021

SUBGROUP DECISIONS WITH SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT

CRG DECISIONS August 2021

Product and indication	Status Assigned	Include in formulary	Notes on Decision	Cost impact	Commissioning/ Service implications	GMMMG decision
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.	**RED**	Add link to chapter 10.	All agents already on formulary as RED in line with NICE TAs for use in treating severe rheumatoid arthritis in adults (DAS28 >5.1). This guidance extends eligible population to include those with moderate disease (DAS28 3.2 to 5.1). CCG commissioned PbRe. Within the scope of the GMMMG moderate rheumatoid arthritis pathway (in development). MGSG agreed with a suggestion to develop a Blueteq form to monitor uptake.	NICE anticipates that this guidance will lead to the overall proportion of the eligible population receiving biological DMARDs or targeted synthetic DMARDs to increase from 15% to 30%. Due to service capacity and COVID restrictions, the GM impact is likely to be £1m--£7m per year by year 5.	Rheumatology service capacity to manage the extra patients is limited as is homecare provision	**Approved** **GMMMG noted the wide variation in estimates for cost impact and await the updated draft of the RA Pathway.**
TA718: Ixekizumab for treating axial spondyloarthritis	**RED**	Add link to chapter 10	CCG commissioned PbRe. Within the scope of the GMMMG ankylosing spondylitis pathway.	This is an additional option alongside existing treatments and NICE expect the impact to be low. GM estimate is less than £270k per year.	It is expected that provision is managed within existing service capacity	**Approved**
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis	**RED**	Add link to chapter 10	CCG commissioned PbRe. Within the scope of the GMMMG ankylosing spondylitis pathway.	This is an additional option alongside existing treatments and NICE expect the impact to be low. GM estimate is less than £270k per year.	It is expected that provision is managed within existing service capacity	**Approved**

SUBGROUP DECISIONS WITHOUT SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT				
MGSG Decisions October 2021				
Product and indication	Notes on Decision	Cost impact	Commissioning/ Service implications	**FINAL DECISION**
Ustekinumab escalation commissioning statement	MGSG heard that as part of the GMMMG IBD pathway review, the working group expressed a desire to review the existing commissioning statement regarding ustekinumab dose escalation. The review found little new evidence none of sufficient quality to change GMMMG's position. The statement has been updated to include both Crohn's disease and ulcerative colitis and any new published evidence. This treatment remains **not routinely commissioned.**  3.2.2 Ustekinumab escalation commissi	Nil	Nil	**Revised statement approved for publication**
GM Antimicrobial Guidelines v9.2	Updates to this guideline have been made based on: • NG198; acne vulgaris • NG199; Clostridioides Difficile • and updated wording to reflect the MHRA safety update advice regarding borax or boric acid buffer contained in chloramphenicol eye drops.  3.5.2 GM Antimicrobial guidel	Nil	Nil	**Approved for publication**
Blueteq form – Bimekizumab for psoriasis	This form was requested urgently and developed to ensure that this treatment could be offered in line with NICE TA273 which has been given a 30 day implementation.	Nil from Blueteq form NICE have stated that no significant resource impacted is expected from the implementation of TA273. This will be confirmed through the GMMMG processes	Nil	**Blueteq form approved for use**

Proposed GM narcolepsy pathway	MGSG agreed to schedule a GM narcolepsy pathway into the current workplan on the understanding that there is no capacity to undertake this work and support through GMMMG processes until at least one of the HCDs pathways in development is completed and published.	TBC	TBC	**Added to MGSG workplan**	

CRG DECISIONS August 2021						
Product and indication	Status Assigned	Include in formulary	Notes on Decision	Cost impact	Commissioning/ Service implications	**FINAL DECISION**
NG199: Clostridioides difficile infection: antimicrobial prescribing	N/A	For info	This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis. Within the scope of GMMMG antimicrobial guidance.	No significant impact on resources expected, that is the resource impact of implementing the whole guideline in England will be less than £5 million per year (or £9,000 per 100,000 population).	Nil	**Link added to formulary**
GMMMG COPD Management plan Inhaler guide	N/A	N/A	This is an update to an existing document and provides a technical review was provided to align with the preferred inhaler choices detailed in the GM COPD Management Plan GMMMG COPD Inhaler Guide - Sept	As per GM COPD management plan	As per GM COPD management plan	**Approved**
All links to MHRA drug safety updates added to formulary as published. Significant alerts where further action is required are highlighted.						